About Us

Board of Directors

Andrew D. Firlik, MD

Previously, Dr. Firlik was General Partner at Foundation Medical Partners concentrating on medical device and healthcare information technology investments. Prior to joining FMP, Dr. Firlik was a venture partner at Sprout Group and Managing Director of its healthcare technology spinout, New Leaf Venture Partners. Dr. Firlik has served as a founder, founding investor, or director of many early stage companies that have grown to become successful market leaders, including Northstar Neuroscience, Inc., NeuroVista Corp. and Intelect Medical, a neuromodulation company acquired by Boston Scientific in January 2011. He studied biology at Cornell University and Oxford University, received his MBA from the University of Pittsburgh, and his MD from Cornell University Medical College.

Mr. Kelly Holman
Co-Founder and Managing Director
Genesys Capital

Mr. Holman is co-Founder and Managing Director of Genesys Capital. Since co-founding the firm in 2000, Mr. Holman has been actively involved in raising over $225 million of venture capital and has been instrumental in deploying over $130 million across 27 investments. He currently serves on the Board of Directors of Epocal, Functional Neuromodulation and InVitae (observer). Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen's University.

Michael A. Greeley
General Partner
Flare Capital Partners

Prior to co-founding Flare Capital Partners, an early-stage healthcare technology venture capital firm which also manages the prior funds of Foundation Medical Partners, Michael served as founding general partner of Flybridge Capital Partners where he led the firm’s healthcare investments.  Previously, Michael focused on emerging-growth company financings with Polaris Venture Partners, was a senior vice president and founding partner of GCC Investments, and held positions at Wasserstein Perella & Co., Morgan Stanley & Co. and Credit Suisse First Boston.

Michael serves on the Investment Committee for the Partners Innovation Fund and Massachusetts Eye & Ear Infirmary. He also serves on the Industry Advisory Board of the Cleveland Clinic, as well as several other boards including the New England Investors’ Committee of Capital Innovation. He was the former chairman of the New England Venture Capital Association and on the Executive Committee of the board of the National Venture Capital Association. Michael earned a B.A. in Chemistry from Williams College and an M.B.A. from Harvard Business School.

Andres Lozano, MD, PhD
Founding Scientist, Chairman of SAB, Director

Dr. Lozano is the Professor and Chairman of the Division of Neurosurgery, and R.R. Tasker Chair in Stereotactic and Functional Neurosurgery of the University Health Network and the University of Toronto. Dr. Lozano originated the concept of treating memory disorders using DBS and co-founded Functional Neuromodulation after successful completion of a pilot study of DBS in six Alzheimer's patients. See Management Bios

Vince Owens
Functional Neuromodulation, Ltd.

Mr. Owens has 25 years of medical device industry experience, including 12 years as CEO of implantable neuromodulation device startups. Prior to joining Functional Neuromodulation as a director in 2012, he was Co-Founder and CEO of Intelect Medical, a developer of neuromodulation technologies including Guide DBS. Mr. Owens led Intelect from startup in 2005 through acquisition by Boston Scientific in 2011. Prior to Intelect, Mr. Owens was CEO of Biomec Cardiovascular, a contract developer of neuromodulation and CRM leads, through acquisition by Enpath Medical (Greatbatch). Mr. Owens serves on the boards of several early stage medical device companies as well as technology commercialization boards at Cornell University and Case Western Reserve University. Mr. Owens received his B.S. in Mechanical Engineering from Carnegie Mellon University and his MBA from Ashland University.

Lothar Krinke, Ph.D.
Board Observer
Vice President and General Manager
Neuromodulation Deep Brain Stimulation
Medtronic, Inc.

Dr. Krinke serves as an observer on the Company's Board of Directors. He is responsible for managing the comprehensive global business strategy for Medtronic's DBS therapies, having previously served as VP of Research and Business Developoment. Krinke joined Medtronic in 2004 as Senior Director, Bioscience Technology Development. With more than 10 years of biomedical strategy expertise from top management consulting firms, he holds a Ph.D. in Molecular Biology from the University at Albany and obtained his undergraduate education at the Technische Univeritaet Braunschweig in Germany.

CAUTION — Investigational device. Limited by Federal law to investigational use.

Functional Neuromodulation, Ltd. | 2 Oliver St., Suite 61 | Boston, MA 02109 | info@fxneuromod.com | 1-866-296-4040
© 2015 Functional Neuromodulation Ltd. All rights reserved.